Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics

Posted on by

Overexpressed in Solid Tumors ADC Currently in a First-in-Human Study NIJMEGEN, Netherlands, April 12, 2023 /PRNewswire/ — Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular Cancer Therapeutics (an…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.